Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95


Real-World Impact of a Decision Support Tool on Colony-Stimulating Factor Use and Chemotherapy-Induced Febrile Neutropenia Among Patients With Breast Cancer.

Agiro A, DeVries A, Malin J, Fisch MJ.

J Natl Compr Canc Netw. 2018 Feb;16(2):162-169. doi: 10.6004/jnccn.2017.7033.


Reducing Overuse of Colony-Stimulating Factors in Patients With Lung Cancer Receiving Chemotherapy: Evidence From a Decision Support-Enabled Program.

Adeboyeje G, Agiro A, Malin J, Fisch MJ, DeVries A.

J Oncol Pract. 2017 Apr;13(4):e337-e345. doi: 10.1200/JOP.2017.020867. Epub 2017 Mar 4.


Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.

Renner P, Milazzo S, Liu JP, Zwahlen M, Birkmann J, Horneber M.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD007913. doi: 10.1002/14651858.CD007913.pub2. Review.


Impact of an electronic tool in prescribing primary prophylaxis with ciprofloxacin or granulocyte colony-stimulating factor for breast cancer patients receiving TC chemotherapy.

Sulpher J, Giguere P, Hopkins S, Dent S.

Support Care Cancer. 2016 Jul;24(7):3185-9. doi: 10.1007/s00520-016-3143-0. Epub 2016 Mar 3.


Risks and consequences of travel burden on prophylactic granulocyte colony-stimulating factor administration and incidence of febrile neutropenia in an aged Medicare population.

Stephens JM, Bensink M, Bowers C, Hollenbeak CS.

Curr Med Res Opin. 2019 Feb;35(2):229-240. doi: 10.1080/03007995.2018.1465906. Epub 2018 May 10.


2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C; European Organisation for Research and Treatment of Cancer.

Eur J Cancer. 2011 Jan;47(1):8-32. doi: 10.1016/j.ejca.2010.10.013. Epub 2010 Nov 20.


Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010-2016: a longitudinal assessment.

Weycker D, Bensink M, Lonshteyn A, Doroff R, Chandler D.

Curr Med Res Opin. 2018 Dec 14:1-15. doi: 10.1080/03007995.2018.1558851. [Epub ahead of print]


The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma.

Gerlier L, Lamotte M, Awada A, Bosly A, Bries G, Cocquyt V, Focan C, Henry S, Lalami Y, Machiels JP, Mebis J, Straetmans N, Verhoeven D, Somers L.

BMC Cancer. 2010 Nov 23;10:642. doi: 10.1186/1471-2407-10-642.


Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy.

Schwartzberg LS, Lal LS, Balu S, Campbell K, Brekke L, DeLeon A, Elliott C, Korrer S.

J Manag Care Spec Pharm. 2018 Oct;24(10):976-984. doi: 10.18553/jmcp.2018.17447. Epub 2018 Apr 24.


Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy.

Chan A, Fu WH, Shih V, Coyuco JC, Tan SH, Ng R.

Support Care Cancer. 2011 Apr;19(4):497-504. doi: 10.1007/s00520-010-0843-8. Epub 2010 Mar 17.


Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.

Mitchell S, Li X, Woods M, Garcia J, Hebard-Massey K, Barron R, Samuel M.

J Oncol Pharm Pract. 2016 Oct;22(5):702-16. doi: 10.1177/1078155215625459. Epub 2016 Jan 13. Review.


Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy.

Skoetz N, Bohlius J, Engert A, Monsef I, Blank O, Vehreschild JJ.

Cochrane Database Syst Rev. 2015 Dec 21;(12):CD007107. doi: 10.1002/14651858.CD007107.pub3. Review.


Importance of Risk Factors for Febrile Neutropenia Among Patients Receiving Chemotherapy Regimens Not Classified as High-Risk in Guidelines for Myeloid Growth Factor Use.

Weycker D, Li X, Barron R, Wu H, Morrow PK, Xu H, Reiner M, Garcia J, Mhatre SK, Lyman GH.

J Natl Compr Canc Netw. 2015 Aug;13(8):979-86.


Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia.

Altwairgi AK, Hopman WM, Mates M.

Curr Oncol. 2013 Jun;20(3):e171-9. doi: 10.3747/co.20.1306.


EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.

Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C; European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party.

Eur J Cancer. 2006 Oct;42(15):2433-53. Epub 2006 Jun 5. Review.


Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practice.

Krzemieniecki K, Sevelda P, Erdkamp F, Smakal M, Schwenkglenks M, Puertas J, Trojan A, Szabo Z, Bendall K, Maenpaa J.

Support Care Cancer. 2014 Mar;22(3):667-77. doi: 10.1007/s00520-013-2021-2. Epub 2013 Oct 24.


Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy.

McCune JS, Sullivan SD, Blough DK, Clarke L, McDermott C, Malin J, Ramsey S.

Pharmacotherapy. 2012 Jan;32(1):7-19. doi: 10.1002/PHAR.1008.


Supplemental Content

Support Center